Akademik Veri Yönetim Sistemi
CLINICAL & TRANSLATIONAL METABOLISM, cilt.23, sa.1, 2025 (ESCI)
The aim of this study was to determine the effect of teriparatide use on bone mineral density (BMD) in women with pregnancy and lactation-associated osteoporosis (PLO) and to evaluate the change in this effect over time. A retrospective evaluation was performed on 11 PLO patients, nine of whom had used teriparatide. BMD assessments were performed using DXA, and fracture assessments were performed using thoracolumbar CT. After treatment, an average of 2.3 years of drug-free follow-up was performed. The mean age was 31.6 years, BMI: 21.4 kg/m2. Number of fractures was 4.6, mean duration of teriparatide use was 6 months, and follow-up from baseline was 39.7 months. Traditional osteoporosis risk factors were rare. The percentage change in lumbar spine BMD compared to the baseline was significant at 13.9% at the 12th month and 24.4% at the end of follow-up (p = 0.001). There was a correlation between the increase in lumbar spine BMD % and the increase in the number of fractures (r = 0.761, p = 0.011) and the duration of teriparatide use (r = 0.737, p = 0.015). There was no significant relationship between the increase in lumbar spine BMD and femoral neck and femur total BMD measurements. In PLO cases, a significant increase in lumbar spine BMD was observed in long-term follow-up. This increase was positively affected by the number of fractures, teriparatide use, and duration. The increase in BMD continued in drug-free follow-up. These results suggest that teriparatide may be a good treatment option in selected PLO cases.